Aktienanalyse zu Orthofix Medical Inc (OFIX)OFIXOrthofix Medical Inc

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Orthofix Medical Inc is currently a hold. The stock is priced at $9.38, which is significantly below the analyst price targets of $13 and $14, indicating potential upside. However, the forward P/E ratio is extremely high at 500, suggesting that the stock may be overvalued based on future earnings expectations. Additionally, the company has reported a year-to-date change of -36.79% and a one-year change of -39.95%, reflecting significant declines in its stock price. The main risk is the company's ongoing net losses, with a net income of -$15.798 million in Q2 2026, which raises concerns about its financial stability and future profitability.

7 analysts cover OFIX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 21.33.